Press
BRC-002 receives Orphan Drug Designation from FDA for Complex Regional Pain Syndrome
BRC announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for the treatment of Complex Regional Pain Syndrome (CRPS) to BRC-002, which is being investigated in an investigator-initiated clinical Phase 1 trial.
Read more →
Cannabinoid Product Holds Promise for Patients in Pain
Scientists at City of Hope are testing a pharmaceutical-grade cannabis-based medicine to determine whether it is effective in treating joint pain in breast cancer patients taking aromatase inhibitors
Biopharmaceutical Research Company Announces First Dose of BRC-002, a First-in-Class Cannabinoid Therapeutic for Complex Regional Pain Syndrome (CRPS), in Investigator-Initiated Study
Biopharmaceutical Research Company Announces First Dose of BRC-002, a First-in-Class Cannabinoid Therapeutic for Complex Regional Pain Syndrome (CRPS), in Investigator-Initiated Study Read more →
First patient received BRC-001, a cannabinoid therapeutic, in a clinical trial investigating supportive care in breast cancer at City of Hope.
City of Hope and Biopharmaceutical Research Company announce first patient has received BRC-001 first-in-class cannabinoid therapeutic, in a clinical trial investigating supportive care in breast cancer Read more →